CURRICULUM VITAE

Alireza Nami MD, FACR

E-MAIL: anami@jmmcri.com
PHONE: 704-248-8577•CELL: 704-582-9949
FAX: 704-780-4284
WEBSITE: www.jmmcri.com

MEDICAL PRACTICES

Joint & Muscle Medical Care/
Joint & Muscle Research Institute
332 Lillington Ave
Charlotte, NC 28204

Ballantyne Rheumatology
8840 Blakeney Professional Drive.
Charlotte NC 28277

EDUCATION:

1998-2000	Rheumatology Fellowship|Albany Medical Center |Albany, NY
1999-1999	Pediatric Rheumatology University of California|San Francisco, CA
1994-1998	Internship/Internal Medicine Residency|Albany Medical Center/Veteran Affairs Medical Center |Albany, NY
1994	Medical Degree| St. George's University |St. George, Grenada,
1989	Bachelor of Science| Portland State University|Portland, OR
1988	Bachelor of Art | Reed College | Portland, OR
1983	Baccalaureate International |Complex Scolaire de Valbonne|Nice, France

PROFESSIONAL EXPERIENCE:

2004-Present	Joint and Muscle Medical Care (**Medical Director/Founder**) 332 Lillington Avenue, Charlotte NC 28204
2005-Present	Joint and Muscle Research Institute (**Medical Director/Founder**) 332 Lillington Avenue, Charlotte NC 28204
2008-Present	Ballantyne Rheumatology (**Medical Director/Founder)** 8840 Blakeney Professional Drive, Charlotte NC 28277

2006-2007	Cleveland Medical Center (**Hospitalist**) Shelby, NC
2001-2004	Victoria Clinic/Stabler Memorial Hospital (**Rheumatologist**) 44 Medical Arts, Suite 3, Greenville AL
2005-2006	Presbyterian Hospital/Forsyth Medical Center(**Hospitalist**) Various NC locations (Charlotte Main, Matthews and Huntersville)
2005-2006	Carolina Medical Center **(Clinical Instructor)** Various Charlotte, NC locations (Main, Mercy and Pineville)
2005-2006	University Health System/Pitt Memorial Hospital **(Hospitalist)** Winston Salem, NC
2005-2006	Piedmont Medical Center (**Hospitalist**) Rockhill, SC

BOARD CERTIFICATIONS:

1999	American Board of Internal Medicine
2008-2018	American Board of Internal Medicine/Rheumatology
2018-2028	American Board of Internal Medicine/Rheumatology

MEMBERSHIPS:

2004 - Present	American College of Rheumatology (ACR)
2004 - Present	European League of Rheumatism (EULAR)
2004 - Present	North Carolina Rheumatology Associates
2004 - Present	Arthritis Foundation
2004 - Present	International Rheumatic Network
2004 - Present	American College of Physician- Internal Medicine
2004 - Present	American Medical Association
2004 - Present	Scleroderma Foundation
2004 - Present	Osteoarthritis Research
2004 - Present	Osteoporosis Foundation
2004 - Present	Lupus Foundation of America

MEDICAL LICENSE:

Active – North Carolina License **#200400560Inactive**: South Carolina License **#282264**

EDUCATIONAL ACCTIVITIES

Speaker:

2011-2013	Pfizer- Tofacitinib: A Novel Oral Biologic in Treatment of Rheumatoid Arthritis
2011-2013	Warner Chilcott: Atelvia as a treatment for Osteoporosis
2011-2013	Takeda Pharmaceuticals: Uloric and Colcrys in Management of Gout
2011-2013	Ferring: Euflexxa in Viscosupplementation of the OA of the Knee

Advisory Boards:

2018	Novartis Pharmaceuticals – 'PULSE' Virtual Advisory Board
2013	UCB Pharmaceuticals (TNF Inhibition)
2013	Ferring Pharmaceuticals (Viscosupplementation)
2013	Amgen Pharmaceuticals (TNF Inhibition)
2010-2011	Amgen Pharmaceuticals (Prolia in Osteoporosis, Enbrel in Rheumatoid Arthritis)
2010-2011	Forest Laboratories (Savella in Fibromyalgia)
2010-2011	Boehinger Ingelheim (COX-1/COX-2 Inhibitions)
2010-2011	UCB Pharmaceuticals (TNF Inhibition)
2010-2011	Endo Pharmaceuticals (Pain management)
2009-2010	Cephalon Pharmaceuticals (Musculoskeletal Pain): Role of Amrix in control of musculoskeletal pain
2009-2010	Novartis Pharmaceuticals: Reclast in Osteoporosis
2008-2009	Ferring Pharmaceuticals (Viscosupplementation)
2008-2009	Abbott Pharmaceuticals (Adalimumab 's role in TNF Inhibition in Rheumatoid Arthritis and Psoriatic Arthritis

Journal Club (JMMCRI):

2006-2008:	Grand Rounds, CMC, Mercy Hospital: Immunology of Connective Tissue Diseases: Role of new biologics in Rheumatoid Arthritis
2005-2006:	Amgen,Role of TNF inhibition in Rheumatology:
2004-2005:	Merck Pharmaceuticals: Cox-2 inhibition in inflammatory and degenerative arthritis
2003-2004:	Aventis/Proctor Gamble - Changing Landscape of Arthritis Pain Management

BASIC SCIENCE RESEARCH ACTIVITIES:

1995-1996	Study of Apoptosis and the role of Methotrexate Wadsworth Research Center, Albany, NY
1994-1995	Role of Glucosamine Glycans in Grave's Ophthalmology Albany Medical Center| Albany, NY

1988	Role of Liposome's in Drug Targeting Oregon Health Sciences University (OHSU)| Portland, OR
1987	Active Oxygen Species in Soybean nodules Reed College/Oregon Institute of Scienceand Technology| Portland, OR
1985	Liquid Crystals and their biophysical properties Georgetown University| Washington, D.C.

CLINICAL RESEACH ACTIVITIES:

PRINCIPAL INVESTIGATOR

MULTI-INDICATION STUDY

1. ***Viela Bio.***
   - **Protocol: VIB7734** A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

LUPUS STUDIES

1. ***Eli Lilly:***
   - **Protocol: H9B-MC-BCDX-** A phase 3b, multicenter, open label study to evaluate the long-term safety and efficacy of subcutaneous LY2127399 in patients with systemic Lupus Erythematosus (SLE)
   - **Protocol: H9B-MC-BCDT -** A Phase 3 Multicenter Randomized Double-Blinded Placebo-Controlled study to evaluate the efficacy and safety of subcutaneous LY2127399 in patients with systemic Lupus Erythematosus
   - **Protocol:I4V-MC-JAIA** - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus

2. ***UCB:***
   - **Protocol: SL0010- BAF** - Phase 3 randomized, double blind, placebo controlled, efficacy and safety of four 12-week treatment cycles (48 weeks total) of Epratuzumab in moderate to severe SLE.

3. ***Pfizer:***
   - **Protocol: B0151006** - A double-blinded randomized, placebo-controlled multicenter dose ranging study to evaluate the efficacy and safety of PF-04236921 in subjects with Systemic Lupus Erythematosus (SLE)

4. ***Medimmune/INC Research:***
   - **Protocol: CD-IA-MEDI-546-1013** -A Phase 2, Randomized Study to Evaluate the efficacy and safety of MEDI-546 in subjects with systemic Lupus Erythematosus
   - **Protocol:CD-IA-MEDI-546-1145** - A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults with Systemic Lupus Erythematosus

5. **Human Genome Science/GlaxoSmithKline**
   - **Protocol: HGS1006-C1113** - A randomized, double blinded, placebo controlled 52-week study to assess adverse events of special interest in adults with active, autoantibody-positive Systemic Lupus Erythematosus receiving Belimumab.
   - **Protocol: 205646 | BLISS BELEIVE-** A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with Rituximab to Adult Subjects with Systemic Lupus Erythematosus (SLE)

6. ***Bristol Myers Squibb***
   - **Protocol: IM128027** - A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects with Active Systemic Lupus Erythematosus
   - **Protocol: IM011021**- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus

7. ***Janssen Research & Development***
   - **Protocol: NOCOMPOUNDLUP0001;** Phase 0Longitudinal Study of Skin and Systemic Biomarkers in Subjects with Active Cutaneous Lupus Erythematosus and In Healthy Volunteers
   - **Protocol: CNTO12755SLE3001**- Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus

8. ***AstraZeneca***
   - **Protocol: D3461C00005:** A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
   - **Protocol: D3461C00009**: A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
   - **Protocol: D3461C00008** – A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in Adult Systemic Lupus

Erythematosus Subjects with Type I Interferon test high result and active skin manifestations

9. ***Biogen***
   - **230LE201-** A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations.

10. **Boston Pharmaceutical**
    - **BOS161721** - A Randomized Double-Blind Phase 1b/2 combined staggered multiple dose escalation study of BOS161721 in Systemic Lupus Erythematosus (SLE) patients on a background of limited standard of care

11. **Idorsia**
    - **Protocol ID-064A202** - A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE

ANKYLOSING SPONDYLITIS

1. ***Eli Lilly***
   - **Protocol:I1F-MC-RHAO(a)-** Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients with Active Ankylosing Spondylitis

2. ***Pfizer***
   - **Protocol: A321119** -A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of Tofacitinib in Subjects with Active Ankylosing Spondylitis (AS)

3. ***Novartis***
   - ***Protocol:*** **CAIN457H2315** - A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis

PSORIATIC ARTHRITIS

1. ***Eli Lilly***
   - ***Protocol*** **-I1F-MC-RHAP** - A multicenter, Randomized, Double Blinded Active and Placebo-Controlled 24 Week study followed by long term evaluation of efficacy and safety of Ixekizumab (LY2439821) in Biologic disease modifying antirheumatic drug naive patients with active Psoriatic Arthritis

2. ***ABBVIE***

- **Protocol M14-197** - A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate
- **Protocol M16-011** - A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo inSubjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to orIntolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

3. ***AMGEN***
   - ***Protocol 20130207*** - Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis
4. **CELGENE**
   - A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaluate the efficacy and safety Of Apremilast (CC-10004) in subjects with Early, oligoarticular Psoriatic Arthritis Despite initial stable treatment with Either NSAIDS and/or ≤ 1 Conventional Synthetic DMARD.

RHEUMATOID ARTHRITIS:

1. ***Roche/Genentech:***
   - ***STAGE*** -A Randomized, Double-Blind, Parallel Group, International Study to evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients with Active Rheumatoid Arthritis Continuing Methotrexate Treatment.
   - ***FILM***-A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab in Combination with Methotrexate (MTX) Compared to MTX Alone in Methotrexate- Naive Patients with Active Rheumatoid Arthritis.
   - ***SCRIPT***-A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients with Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-α Therapy.
   - **ROSE-** A Randomized, Double-Blind, Parallel-Group study to evaluate the safety and efficacy of tocilizumab versus placebo in combination with Disease Modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis.
   - ***ACT-STAR*** - An open-label, randomized study to Evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis who have inadequate response to current non-biologic or biologic DMARDs.

2. ***Abbott***
   - ***M10-261***-A Multi-Center, Randomized, Double-blind, Placebo-controlled Study comparing 80mg of Adalimumab with placebo, and Demonstrating the Non-inferiority of Monthly 80mg Adalimumab Dosing compared with 40mg Adalimumab Every Other Week Dosing.

3. ***Johnson&Johnson-Janssen***
   - ***GO-SAVE*** - A Golimumab Phase 3b, Multicenter, switch Assessment of subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who have Inadequate Disease Response Despite Treatment with Etanercept (ENBREL®) or Adalimumab (HUMIRA®).
   - **Protocol CNTO148ART3003:** A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment with Infliximab (REMICADE®)

4. ***AstraZeneca***
   - ***OSKIRA-2*** – A Phase III, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs.
   - ***OSKIRA-3*** – A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patient with Inadequate Response to a TNF-alpha antagonist.
   - ***OSKIRA-4:*** A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Monotherapy with Fostamatinib Disodium in Rheumatoid Arthritis Patient with RA.
   - ***OSKIRA-X:*****Protocol - OSKIRA-X:** A long term Extension Study to assess the safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis

5. ***Amgen***
   - ***Protocol 20110186*** -A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects with Rheumatoid Arthritis

6. ***Abbvie***
   - **Protocol: M14-465** -A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
   - **Protocol: M13-542** - A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to BiologicDMARDs (bDMARDs)

7. **Gilead**
   - **Protocol: GS-US-417-0302-** A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-Rheumatic Drug(s) (csDMARDs) to Subjects with Moderately to Severely Active

Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment

- **Protocol: GS-US-417-0303-** ARandomized, Double-blind, Placebo-controlled, Multicenter, Phase3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are Naïve to MTX Therapy
- **Protocol:GS-US-417-0304** - A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis

SCLERODERMA

1. ***Roche***

- **Protocol WA29767:** A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study to assess the efficacy and safety of Tocilizumab versus Placebo in patients with Systemic Sclerosis

VACCINATION AND SAFETY IN RA:

1. ***Roche***

- **Protocol WA25204 | ENTRACTE** -A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA).

2. ***UCB***

- ***RA0017***- A Phase 4, Randomized, Single Blind, Placebo-Controlled, Multicenter study to evaluate the immunogenicity of pneumococcal and influenza vaccine in adult subjects with rheumatoid arthritis receiving certolizumab pegol or placebo.

3. ***Pfizer***

- ***PRECISION***: A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen.

LUPUS NEPHRITIS

1. ***Aurinia***

- **Protocol:**AUR-VCS-2012-01-A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving Remission in Patients with Active Lupus Nephritis
- **Protocol:** AUR-VCS-2016-01 **(Aurora)** - A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (Voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis

OSTEOARTHRITIS:

1. ***Pfizer***
   - ***A4091026*** - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Tanezumab on Peripheral Nerve Function in Patients with Osteoarthritis.

2. ***Axsome***
   - ***Protocol: AXS02-K301*-COAST-1:** Clinical Knee Osteoarthritis Symptom Treatment 1 StudyA Randomized, Double-blind, Placebo-controlled Trial to Assess the efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Knee Osteoarthritis Associated with Bone Marrow Lesions.

OSTEOPOROSIS

1. ***Amgen***
   - ***Protocol:* 20150120-** A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women with Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab via Autoinjector/Pen vs Healthcare Provider-administered Romosozumab via Prefilled Syringe

SJÖGREN'S

1. **Bristol Myers Squibb**
   - ***Protocol: IM101-603*** - A Phase 3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjogren's Syndrome
2. **Gilead**
   - **Protocol: GS-US-445-4189** - A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren's Syndrome

PAIN MANAGEMENT AND THERAPEUTICS:

1. ***Pfizer***
   - ***Protocol: CONVERT***: A Multi-Center, Primary Care Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, with Chronic, Moderate to Severe Pain, to EMBEDA Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion.
2. ***Pria Pharmaceutical***
   - Study of Tramadol ER for the Management of Moderate to Moderately Severe Chronic Pain of Osteoarthritis of the Hip and Knee in Adults.

3. ***Pain and Therapeutics***:
   - Study of PTI-821 in Patients with Moderate to Severe Chronic Pain due to Osteoarthritis of the Hip and Knee.

REGISTRIES:

1. **CLEAR** (Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis): HLA-DR alleles and cytokine polymorphism.
2. **CORRONA** (Consortium of Rheumatology Research of North America): Data that identifies patient's responses to particular treatments or treatment combinations.
3. **CORRONA CERTAIN**: Consortium of Rheumatology Research of North America): Data that identifies patient's responses to treatments or treatment combinations. Initiation of a biologic agent is followed in patientsfulfilling RA diagnostic criteria
4. **SUNSTONE** – A Long Term Study of the Safety of Rituxan in Patients with Rheumatoid Arthritis after an Inadequate Response to previous Anti-TNF Therapy (5-year study completed).
5. **OPERA** - Observation of Productivity in Employed patients with Rheumatoid Arthritis Study.
6. **SLE REGISTRY** A Long-Term Study of the Safety of Rituxan in Patients with Rheumatoid Arthritis after an Inadequate response to TNF inhibitors
7. **Sable - HGS1006-C1124** - A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without BENLYSTA (belimumab)
8. **CORRONA PSA/SPA** - Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry

LANGUAGES

Persian, French, Spanish, Russian

My signature verifies that the information on this curriculum vitae is accurate and updated annually.

Investigator's Signature Jan 14, 2019 **Date**